BIODEFENSE MARKET ANALYSIS

Biodefense Market Size and Trends

The global biodefense market is estimated to be valued at USD 16.51 Bn in 2024 and is expected to reach USD 27.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.3% from 2024 to 2031.

To learn more about this report, Request sample copy

The increased investments by government and private organizations to combat biological threats along with the rising incidence of pandemics and infectious diseases are fueling the market growth. The biodefense market is witnessing positive trends with increasing R&D activities focused on developing novel therapies and prevention measures. Furthermore, growing awareness regarding potential bio-threats, availability of government funding, and partnerships between private companies and research institutes are providing opportunities for innovation. However, lengthy product approval timelines and high costs associated continue to hamper the market growth.

Increasing Government initiatives and funding

Government initiatives and funding have played a key role in spurring innovation and development in the biodefense sector. In recent years, many developed nations have acknowledged biodefense and pandemic preparedness as strategically important objectives. For example, the U.S. allocated US$9 billion towards biodefense between 2021 and 2022 according to data from the U.S. Department of Health and Human Services. These funds are being utilized to bolster stockpiles of critical medical countermeasures like vaccines and therapeutics. Several projects focused on developing rapid response capabilities, such as new vaccine platforms allowing production within months, have received major government grants.

For instance, in April 2022, in Q1 2022, Emergent Bioscience, specialty biopharmaceutical company reported a rise of US$ 48.6 million in revenue from Anthrax vaccines compared to Q1 2021. This increase primarily stems from the scheduling of deliveries to the United States Government (USG), notably to the Strategic National Stockpile (SNS). Furthermore, in September 2021, the company secured a contract modification worth around US$ 399 million for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted), extending the delivery of additional doses through March 2023.

To learn more about this report, Request sample copy

Increasing Threat of Pandemics

The COVID-19 pandemic has been an important learning experience that highlighted vulnerabilities in healthcare systems and unpreparedness for global outbreaks. It caused widespread fatalities and completely disrupted economies worldwide. Such public health crises occurring more frequently has increased awareness around resilience against infectious diseases. This is prompting greater focus on bio-surveillance, vaccine & therapeutic development as well as bolstering emergency response mechanisms. Furthermore, factors like climate change, rising global travel, and changing interaction with wildlife are feared to raise the chances of zoonotic disease transmission in future. Scientists have warned of more pandemics breaking out in coming decades. To minimize the impact of health emergencies, governments are significantly ramping up investments into pandemic prevention, preparedness, and response. This is stimulating strong demand across various bio-defense product categories including personal protective equipment, diagnostics, broad-spectrum antivirals, facility safety solutions, and stockpiling of medical countermeasures. The looming risk of future pandemics is a key driver boosting the broader bio-defense market.